Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| JOHNSON & JOHNSONJNJ · Entity 2722 | Vice Chair, Exec Committee | February 12, 2021 | February 18, 2021 |
| TAKEDA PHARMACEUTICAL CO LTDTAK · Entity 2662 | Director | July 01, 2026 | July 06, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
JOHNSON & JOHNSON
Report date February 12, 2021 · Filed February 18, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 275,547.3732 |
Ending reported balance
After 2021-02-12 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2021-02-12 · Exercise / conversion · Acquired 29,452 · Balance 284,254.3732 F1: Performance Share Units awarded under Issuer's Long-Term Incentive Plan on February 12, 2018; converted into shares of Common Stock upon vesting. Row 2 · 2021-02-12 · Exercise / conversion · Acquired 5,610 · Balance 289,864.3732 F2: Restricted Share Units awarded under Issuer's Long-Term Incentive Plan on February 12, 2018; converted into shares of Common Stock upon vesting. Row 3 · 2021-02-12 · Tax withholding · Disposed 1,592 · Balance 288,272.3732 F3: Shares withheld for payment of taxes upon vesting of Restricted Share Units. Row 4 · 2021-02-12 · Tax withholding · Disposed 12,725 · Balance 275,547.3732 F4: Shares withheld for payment of taxes upon vesting of Performance Share Units. |
| Performance Share UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2021-02-12 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2021-02-12 · Exercise / conversion · Disposed 29,452 · Balance 0 F1: Performance Share Units awarded under Issuer's Long-Term Incentive Plan on February 12, 2018; converted into shares of Common Stock upon vesting. |
| Restricted Share UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2021-02-12 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2021-02-12 · Exercise / conversion · Disposed 5,610 · Balance 0 F2: Restricted Share Units awarded under Issuer's Long-Term Incentive Plan on February 12, 2018; converted into shares of Common Stock upon vesting. |
Filing footnotes · ownership attribution and instrument terms
F1: Performance Share Units awarded under Issuer's Long-Term Incentive Plan on February 12, 2018; converted into shares of Common Stock upon vesting.
F2: Restricted Share Units awarded under Issuer's Long-Term Incentive Plan on February 12, 2018; converted into shares of Common Stock upon vesting.
F3: Shares withheld for payment of taxes upon vesting of Restricted Share Units.
F4: Shares withheld for payment of taxes upon vesting of Performance Share Units.
TAKEDA PHARMACEUTICAL CO LTD
Report date July 01, 2026 · Filed July 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 3,800 |
Reported balance
After 2026-07-01 transaction · row 1
1 source rowRow 1 · 2026-07-01 · Grant · Acquired 3,800 · Balance 3,800 F1: Represents an award of restricted stock units (RSU). Each RSU represents a contingent right to receive one Ordinary Share, which will be converted into an equivalent number of American Depositary Shares following vest. The RSUs vest on June 1, 2029. |
| Tax Obligation AwardSEC Table II · derivative / convertible security · Expires 2029-06-01 | Direct | 1,307 |
Reported balance
After 2026-07-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-07-01 · Grant · Acquired 1,307 · Balance 1,307 F2: Each Tax Obligation Award is the economic equivalent of one Ordinary Share that, upon vest, will be converted to a cash payment primarily to cover tax obligations at the then-current market price of the Ordinary Shares. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents an award of restricted stock units (RSU). Each RSU represents a contingent right to receive one Ordinary Share, which will be converted into an equivalent number of American Depositary Shares following vest. The RSUs vest on June 1, 2029.
F2: Each Tax Obligation Award is the economic equivalent of one Ordinary Share that, upon vest, will be converted to a cash payment primarily to cover tax obligations at the then-current market price of the Ordinary Shares.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 08, 2013 Filed Feb 12, 2013 23:25 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | Exercise / conversionRestricted Share Units · Derivative | 18,391 | $0.00 | $0.00 |
DisclosureSEC source: 0000200406-13-000021 · edgar.xml · derivative · entry 3 Stoffels Paulus · CIK 0001559387 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,391 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each Restricted Share Unit, awarded under Issuer's Long-Term Incentive Plan on February 8, 2010, represents a contingent right to receive one share of Common Stock and vests three years after date of grant. F4 · derivative.expiration_date: Not applicable. Read SEC document |
| February 08, 2013 Filed Feb 12, 2013 23:25 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | Tax withholdingCommon Stock | 9,536 | $75.17 | $716,821.12 |
DisclosureSEC source: 0000200406-13-000021 · edgar.xml · nonDerivative · entry 2 Stoffels Paulus · CIK 0001559387 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,954 F2 · shares: Shares withheld for the payment of taxes upon vesting of Restricted Share Units. Read SEC document |
| February 08, 2013 Filed Feb 12, 2013 23:25 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | Exercise / conversionCommon Stock | 18,391 | $0.00 | $0.00 |
DisclosureSEC source: 0000200406-13-000021 · edgar.xml · nonDerivative · entry 1 Stoffels Paulus · CIK 0001559387 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,490 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: All 99 shares held under Issuer's Dividend Reinvestment Plan. Read SEC document |
| January 16, 2013 Filed Jan 18, 2013 22:05 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | GrantPerformance Share Units · Derivative | 28,242 | $0.00 | $0.00 |
DisclosureSEC source: 0000200406-13-000007 · edgar.xml · derivative · entry 4 Stoffels Paulus · CIK 0001559387 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,242 Underlying: Common Stock · 28,242 shares Expires not disclosed F2 · security: Awarded under Issuer's Long-Term Incentive Plan. F4 · derivative.exercise_price: Each Performance Share Unit converts into one share of Common Stock upon distribution in the first quarter of 2016 based on a performance factor. F4 · derivative.exercise_date: Each Performance Share Unit converts into one share of Common Stock upon distribution in the first quarter of 2016 based on a performance factor. F4 · derivative.expiration_date: Each Performance Share Unit converts into one share of Common Stock upon distribution in the first quarter of 2016 based on a performance factor. Read SEC document |
| January 16, 2013 Filed Jan 18, 2013 22:05 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | GrantRestricted Share Units · Derivative | 11,297 | $0.00 | $0.00 |
DisclosureSEC source: 0000200406-13-000007 · edgar.xml · derivative · entry 3 Stoffels Paulus · CIK 0001559387 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,297 Underlying: Common Stock · 11,297 shares Expires not disclosed F2 · security: Awarded under Issuer's Long-Term Incentive Plan. F3 · derivative.exercise_price: Each Restricted Share Unit represents a contingent right to receive one share of Common Stock and vests three years after date of grant. F3 · derivative.expiration_date: Each Restricted Share Unit represents a contingent right to receive one share of Common Stock and vests three years after date of grant. Read SEC document |
| January 16, 2013 Filed Jan 18, 2013 22:05 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | GrantEmployee Stock Options (Right to Buy) · Derivative | 227,692 | $0.00 Strike: $72.54 | $0.00 |
DisclosureSEC source: 0000200406-13-000007 · edgar.xml · derivative · entry 2 Stoffels Paulus · CIK 0001559387 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 227,692 Underlying: Common Stock · 227,692 shares Expires 2023-01-13 F2 · security: Awarded under Issuer's Long-Term Incentive Plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.